.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Merck
Covington
QuintilesIMS
Healthtrust
Queensland Health
Medtronic
Johnson and Johnson
Fuji
Mallinckrodt

Generated: July 25, 2017

DrugPatentWatch Database Preview

SITAVIG Drug Profile

« Back to Dashboard

Which patents cover Sitavig, and when can generic versions of Sitavig launch?

Sitavig is a drug marketed by Epi Hlth and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in SITAVIG is acyclovir. There are fifty-five drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the acyclovir profile page.

Summary for Tradename: SITAVIG

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list113
Patent Applications: see list6,847
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SITAVIG at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Epi Hlth
SITAVIG
acyclovir
TABLET;BUCCAL203791-001Apr 12, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SITAVIG

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,211,466Mucosal bioadhesive slow release carrier for delivering active principles► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SITAVIG

Country Document Number Estimated Expiration
Japan2009531411► Subscribe
European Patent Office2509586► Subscribe
China101410092► Subscribe
South Korea101335185► Subscribe
Spain2335712► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SITAVIG

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Healthtrust
Deloitte
Moodys
Federal Trade Commission
Queensland Health
Accenture
Colorcon
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot